XO functional activity in the liver was also increased in hyperuricemia mice and significantly decreased in MOL-FP administration mice (Figure 1D), indicating that MOL-FP administration was able to antagonize hepatic XO activity in hyperuricemia mice. The gene discussed is XDH; the disease is hyperuricemia.